
- /
- Supported exchanges
- / F
- / 4AB.F
AbbVie Inc (4AB F) stock market data APIs
AbbVie Inc Financial Data Overview
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get AbbVie Inc data using free add-ons & libraries
Get AbbVie Inc Fundamental Data
AbbVie Inc Fundamental data includes:
- Net Revenue: 57 367 M
- EBITDA: 27 366 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-09
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
AbbVie Inc News

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of th...


AbbVie Inc. (NYSE:ABBV) is favoured by institutional owners who hold 75% of the company
Key Insights Given the large stake in the stock by institutions, AbbVie's stock price might be vulnerable to their trading decisions A total of 25 investors have a majority stake in the company with ...

AbbVie (ABBV) Surpasses Market Returns: Some Facts Worth Knowing
AbbVie (ABBV) closed at $190.58 in the latest trading session, marking a +2.25% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.32% for the day. Meanwhile, the Do...

How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?
AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on two blood-cancer drugs — Imbruvica and Venclexta — it has since built a b...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.